Vergelijking
CJC-1295 vs. IGF-1 LR3
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Groei
Groei
CAS-nr.
geen gegevens
143045-27-6
Molecuulmassa
3647.3 g/mol
9117.6 g/mol
Halfwaardetijd
144 h
21 h
Sequentie
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACMFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSAWerkingsmechanisme
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
IGF-1 LR3
IGF-1 LR3 is a recombinantly produced variant of human IGF-1. Two changes define its properties: (1) at position 3, glutamic acid is replaced by arginine; (2) a 13-amino-acid sequence is added at the N-terminus ('Long'). Both modifications drastically reduce affinity for the six IGF-binding proteins (IGFBP-1 to -6) that normally bind native IGF-1 in the blood and regulate its availability at the receptor. As a result, a larger fraction of the molecule is freely available to bind the type-1 IGF receptor (IGF-1R) — the same receptor as native IGF-1. In preclinical models and cell culture, LR3 IGF-1 therefore acts as a more potent agonist than unmodified IGF-1. The downstream signalling pathway (PI3K/Akt and MAPK) is identical to that of IGF-1; the modification changes bioavailability, not the receptor target.
Bewijsbasis
Hoogste bewijs
Humane studie
Diermodel
Studies
4
4
waarvan bij mensen
3
0
Geregistreerde effecten
3
4
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
3
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between CJC-1295 and IGF-1 LR3?
- CJC-1295 is classified as "Groei", while IGF-1 LR3 is classified as "Groei". CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. IGF-1 LR3: Synthetic analogue of insulin-like growth factor 1 (IGF-1) carrying an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications lower binding to IGF-binding proteins and extend its duration of action relative to native IGF-1. LR3 IGF-1 is primarily an established cell-culture reagent (serum-free media, bioprocessing); it is NOT an approved human medicine. Use in the bodybuilding grey market is described; as an IGF-1 analogue, LR3 IGF-1 falls under the WADA anti-doping prohibition. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CJC-1295 or IGF-1 LR3?
- The highest available evidence level is "Humane studie" for CJC-1295 and "Diermodel" for IGF-1 LR3. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CJC-1295 and IGF-1 LR3 in Germany and the United States?
- Duitsland: CJC-1295 — Niet goedgekeurd, IGF-1 LR3 — Niet goedgekeurd. Verenigde Staten: CJC-1295 — Alleen onderzoek, IGF-1 LR3 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.